Novavax Financials - Benzinga

Novavax Inc

NVAXNASDAQ

Trade with Public

Trade with Public

$10.63

0.030.28%

In chiusura: Sep 25, 5:00 PM EST

$10.67

0.040.38%

Post-mercato: Sep 25, 7:57 PM EST

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Opzioni Rapporto azionario

Novavax Financials

Novavax (NVAX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Novavax Raises FY2026 Sales Guidance from $230.000M-$270.000M to $235.000M-$275.000M vs $389.234M Est

Novavax (NASDAQ:NVAX) raises FY2026 sales outlook from $230.000 million-$270.000 million to $235.000 million-$275.000 million vs $389.234 million estimate.

Benzinga Newsdesk

PRO
Novavax Q2 EPS $(0.32) Beats $(0.37) Estimate, Sales $56.698M Beat $52.513M Estimate

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

Why Novavax Stock Is Trading Higher On Wednesday?

Novavax shares rise after Q1 revenue beat; partnerships, credit facility, and technical levels shape outlook amid shift to net loss.

Vandana Singh

PRO
Novavax Affirms FY2026 Sales Guidance of $230.000M-$270.000M vs $393.277M Est

Novavax (NASDAQ:NVAX) affirms FY2026 sales outlook from $230.000 million-$270.000 million to $230.000 million-$270.000 million vs $393.277 million estimate.

Benzinga Newsdesk

PRO
Novavax Q1 EPS $(0.06), Sales $139.514M Beat $78.323M Estimate

Novavax (NASDAQ:NVAX) reported quarterly losses of $(0.06) per share. This is a 102.05 percent decrease over earnings of $2.93 per share from the same period last year. The company reported quarterly sales of $139.514

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved